PT-141 (Bremelanotide) 10mg

PT-141 represents the first drug in a novel category known as melanocortin agonists, which are being developed for the treatment of sexual dysfunction. Its mechanism of action may provide notable safety and effectiveness advantages compared to existing treatments, as it influences the sexual function pathway without directly targeting the vascular system. Clinical findings suggest that PT-141 could be beneficial for a wide variety of patients experiencing erectile dysfunction. The nasal delivery form of PT-141 under development is as user-friendly as oral therapies, more tolerable than invasive erectile dysfunction treatments like injections and trans-urethral pellets, and seems to offer a quick onset of effects.

This medication may even surpass Viagra in popularity, which operates by directly increasing blood flow to sexual organs. For many women, however, the primary issue is a lack of libido rather than physical impediments. In contrast, PT-141 focuses on stimulating the brain's arousal center, making it more likely to rekindle sexual interest. The drug's most appealing characteristic is its potential to enhance sexual arousal in women, leading some to refer to it as the "Viagra for women." Research conducted with mice revealed that female mice treated with PT-141 exhibited increased mating behaviors towards male mice, indicating heightened sexual desire.